295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Strong interest among schools in incentive to promote healthy and sustainable eating Schools are highly interested in the promotional incentive of a programme teaching young children to eat healthy from a young age. The incentive is called ‘Let’s go outside for tasty food!’ or Lekker naar buiten! in Dutch. 2,273 schools applied for the funding over a three year period.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
Number of participants in Combined Lifestyle Intervention tops 73,000 By the end of 2022, the number of participants in the Combined Lifestyle Intervention (CLI) had grown to over 73,000. This is according to a semi-annual report by RIVM. The figure represents a 51% increase since the end of May 2022. The number of participants was around 48,000 at that time.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Reducing greenhouse gas emissions via procurement partnerships By optimising collaboration when purchasing products and services, the government can reduce greenhouse gas emissions. This was the conclusion of a study by the National Institute for Public Health and Environmental Protection (RIVM) into so-called 'buyer groups'.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.